| AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (NCT05377658) | Henan Cancer Hospital | 2022-07-26 |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer (NCT05275673) | Faeth Therapeutics | 2022-07-21 |
| Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC (NCT05448781) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2022-07-20 |
| CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease (NCT05257967) | British Columbia Cancer Agency | 2022-07-18 |
| Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (NCT05440916) | University Medical Centre Maribor | 2022-07-14 |
| Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer (NCT05183932) | Washington University School of Medicine | 2022-07-14 |
| Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC (NCT05400577) | Fox Chase Cancer Center | 2022-07-13 |
| Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients (NCT05758116) | Peking University Cancer Hospital & Institute | 2022-07-07 |
| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (NCT05480865) | Navire Pharma Inc., a BridgeBio company | 2022-07-06 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701) | Pfizer | 2022-07-05 |
| Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via Imaging (NCT05254132) | OncoRadiomics | 2022-07-01 |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients (NCT04638751) | Persephone Biosciences | 2022-07-01 |
| Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy (NCT05383716) | Peking Union Medical College Hospital | 2022-07-01 |
| Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery (NCT05648370) | Guangdong Provincial People's Hospital | 2022-07-01 |
| Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients (NCT05450081) | Hunan Province Tumor Hospital | 2022-06-30 |
| Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (NCT05785208) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-06-28 |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (NCT05286294) | Oslo University Hospital | 2022-06-28 |
| GEMINI-NSCLC: NSCLC Biomarker Study (NCT05236114) | Tempus AI | 2022-06-22 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors (NCT05256381) | SOTIO Biotech AG | 2022-06-21 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer (NCT05430009) | VA Ann Arbor Healthcare System | 2022-06-17 |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (NCT05142189) | BioNTech SE | 2022-06-17 |
| A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (NCT05180422) | Criterium, Inc. | 2022-06-15 |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (NCT05429320) | Memorial Sloan Kettering Cancer Center | 2022-06-15 |
| Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (NCT05132075) | Novartis Pharmaceuticals | 2022-06-15 |
| Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients (NCT05378334) | Guangzhou University of Traditional Chinese Medicine | 2022-06-15 |
| A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NCT05047250) | Hoffmann-La Roche | 2022-06-14 |
| Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer (NCT05424029) | Memorial Sloan Kettering Cancer Center | 2022-06-14 |
| Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors (NCT05460481) | Hunan Cancer Hospital | 2022-06-12 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500) | Bristol-Myers Squibb | 2022-06-09 |
| Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (NCT05244213) | Guangdong Provincial People's Hospital | 2022-06-04 |
| Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (NCT05195632) | Pierre Fabre Medicament | 2022-06-02 |
| Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients (NCT05369312) | Betta Pharmaceuticals Co., Ltd. | 2022-06-01 |
| Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer (NCT05387512) | Affiliated Hospital of Nantong University | 2022-06-01 |
| A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer (NCT05329025) | Qilu Pharmaceutical Co., Ltd. | 2022-06-01 |
| A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. (NCT05361564) | Yonsei University | 2022-06-01 |
| Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) (NCT05085054) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-06-01 |
| FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT05395052) | Fate Therapeutics | 2022-05-31 |
| A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors (NCT05366478) | Suzhou BlueHorse Therapeutics Co., Ltd. | 2022-05-30 |
| Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NCT05186974) | Gilead Sciences | 2022-05-30 |
| Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases (NCT04967417) | Samsung Medical Center | 2022-05-26 |
| Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NCT05341583) | Betta Pharmaceuticals Co., Ltd. | 2022-05-24 |
| Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells) (NCT04957602) | Hospices Civils de Lyon | 2022-05-20 |
| SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (NCT05351788) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-05-20 |
| Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy (NCT05469022) | Konkuk University Medical Center | 2022-05-19 |
| A Study of AL8326 in Non-Small Cell Lung Cancer (NCT06794957) | Advenchen Laboratories, LLC | 2022-05-19 |
| Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC (NCT05418660) | University of Milano Bicocca | 2022-05-19 |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (NCT05200481) | Intergroupe Francophone de Cancerologie Thoracique | 2022-05-18 |
| Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (NCT05319886) | The First Affiliated Hospital of Xinxiang Medical College | 2022-05-16 |
| A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC (NCT05360979) | Second Xiangya Hospital of Central South University | 2022-05-15 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer (NCT05348668) | Anhui Provincial Hospital | 2022-05-09 |
| HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05102214) | Shanghai Henlius Biotech | 2022-05-03 |
| PD-L1 Expression in Lung Cancer (NCT04992715) | NanoMab Technology (UK) Limited | 2022-05-03 |
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors (NCT07121829) | Day One Biopharmaceuticals, Inc. | 2022-05-02 |
| Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer (NCT05241028) | Hebei Medical University Fourth Hospital | 2022-05-01 |
| High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases (NCT05379803) | Hunan Province Tumor Hospital | 2022-05-01 |
| A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (NCT05354102) | Biomica Ltd. | 2022-05-01 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| Multiomics Tumor Evolution Model of NSCLC (NCT05352035) | Peking University People's Hospital | 2022-04-20 |
| Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC (NCT05813522) | First Affiliated Hospital of Zhejiang University | 2022-04-15 |
| Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer (NCT06706713) | BeBetter Med Inc | 2022-04-15 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NCT05061550) | AstraZeneca | 2022-04-14 |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (NCT05288205) | Allist Pharmaceuticals, Inc. | 2022-04-14 |
| Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care (NCT05254795) | Timothy Mullett | 2022-04-13 |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT05267626) | Aulos Bioscience, Inc. | 2022-04-04 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (NCT05194735) | Alaunos Therapeutics | 2022-04-04 |
| A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer (NCT05171777) | Hoffmann-La Roche | 2022-04-04 |
| Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment (NCT05306652) | AUSL Romagna Rimini | 2022-04-04 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (NCT05296564) | Hadassah Medical Organization | 2022-04-01 |
| Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer (NCT05517083) | Pusan National University Hospital | 2022-04-01 |
| Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer (NCT05284539) | Hunan Province Tumor Hospital | 2022-04-01 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations (NCT05256290) | Black Diamond Therapeutics, Inc. | 2022-03-31 |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (NCT05062980) | Genprex, Inc. | 2022-03-30 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| Using ctDNA to Determine Therapies for Lung Cancer (NCT04966663) | University Health Network, Toronto | 2022-03-28 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT04928846) | AbbVie | 2022-03-25 |
| Personalized DC Vaccines in Non Small Cell Lung Cancer (NCT05195619) | Centre Hospitalier Universitaire Vaudois | 2022-03-22 |
| A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). (NCT05240131) | Galecto Biotech AB | 2022-03-15 |
| SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (NCT04878107) | Wuhan University | 2022-03-15 |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (NCT05238883) | HiFiBiO Therapeutics | 2022-03-10 |
| Tarlox and Sotorasib in Patients With KRAS G12C Mutations (NCT05313009) | Medical University of South Carolina | 2022-03-07 |
| A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (NCT05234606) | Silverback Therapeutics | 2022-03-01 |
| Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer (NCT05252065) | Guizhou Medical University | 2022-02-28 |
| A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China (NCT05337163) | Creative Biosciences (Guangzhou) Co., Ltd. | 2022-02-25 |
| Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE) (NCT05430802) | Tang-Du Hospital | 2022-02-24 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (NCT05121948) | HiberCell, Inc. | 2022-02-23 |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (NCT05120349) | AstraZeneca | 2022-02-21 |
| Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC (NCT05218759) | Shanghai Chest Hospital | 2022-02-21 |
| An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC (NCT05252091) | Henan Cancer Hospital | 2022-02-20 |
| Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research (NCT05669105) | Sanguine Biosciences | 2022-02-19 |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (NCT05211895) | AstraZeneca | 2022-02-18 |
| A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (NCT05141357) | HUYABIO International, LLC. | 2022-02-15 |
| Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device (NCT06789224) | Lindis Bloodcare GmbH | 2022-02-15 |
| A Study of PRT2527 in Participants With Advanced Solid Tumors (NCT05159518) | Prelude Therapeutics | 2022-02-14 |
| First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies (NCT05627960) | A&G Pharmaceutical Inc. | 2022-02-14 |
| NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts (NCT04960059) | The Christie NHS Foundation Trust | 2022-02-11 |
| Comprehensive Geriatric Assessment in Elderly Non-Small Cell Lung Cancer Patients (NCT05230888) | University of Hull | 2022-02-09 |
| Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NCT06268210) | Yonsei University | 2022-02-07 |